Allergy Therapeutics (AGY)
Allergy Therapeutics to present on 7 March 2018 at the Shares and AJ Bell Spotlight Evening in London
15/02/2018 - 09:24 StockMarketWire
If you are looking for some investment ideas for your ISA, then come along the Shares and AJ Bell Investor Evening in Lo...
12/02/2018 - 08:38 StockMarketWire
Allergy Therapeutics plc announced Monday that recruitment has been completed in its grass allergy Phase II study with r...
12/02/2018 - 07:00 RNS
RNS Number: 5209E Allergy Therapeutics PLC 12 February 2018 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Completion of recruitment in PQ Grass Phase II trial Trial running ahead of schedule with data now due in early H2 2018 12 February 2018 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specia...
02/02/2018 - 07:15 RNS
RNS Number: 7100D Allergy Therapeutics PLC 02 February 2018 Hardman Research: Growth in a tough market Growth in a tough market: AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in th...
|06-12-11||Markets: FTSE 100 flat on Tuesday||Interactive Investor|
|26-04-11||Markets: Manufacturing data lifts FTSE 100||Interactive Investor|
|26-04-11||FDA approval lifts shares in Allergy Therapeutics||Interactive Investor|
|28-03-11||Markets: FTSE 100 trims gains on Monday||Interactive Investor|
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment